Vor Bio initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Vor Bio (VOR) with an Overweight rating and $30 price target The firm believes the company’s telitacicept is “derisked” in two indications that represent $5B in peak sales. The Phase 3 generalized myasthenia gravis data in the first half of 2027 could be major inflection for the shares, the analyst tells investors in a research note. Wells thinks the stock can work ahead of the readout.